Mode
Text Size
Log in / Sign up
N/A N=48 Treatment

Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis

Postmenopausal Osteoporosis · Osteopenia · Jaw, Edentulous, Partially

Enrolled (actual)
48
Serious AEs
22.9%
Results posted
Nov 2019
Primary outcome: Primary: Marginal Bone Level Alterations — -0.15; -0.06 millimeter

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
OsseoSpeed™ (Device)
Age
Adult, Older Adult · 60+ yrs
Sex
Female
Sponsor
Dentsply Sirona Implants and Consumables
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Marginal Bone Level Alterations
-0.15; -0.06

Summary

The overall objective of the study is to compare treatment with the ASTRA TECH Implant System, OsseoSpeed™ implant in the maxilla of postmenopausal women with and without systemic osteoporosis. The hypothesis is that there will be no difference in marginal bone level alterations between the two groups.

Eligibility Criteria

Inclusion Criteria

  • Provision of informed consent
  • Postmenopausal women aged 60 years and over
  • In need of 2-8 implants in maxilla
  • A history of edentulism in the area of implant treatment of at least 6 months.
  • A Bone Mineral Density (BMD) value suitable either for group A or group B:
  • Group A (Osteoporosis/osteopenia): BMD at least 2 standard deviations (SD) below mean peak bone density of young adults for the spine and total hip (T-score = -2 SD or less). Absolute values (g/cm2) will be used.
  • Group B (Control): BMD not more than 1 standard deviation below mean peak bone density of young adults for the spine and total hip (T-score = -1 SD or more). Absolute values (g/cm2) will be used.

Exclusion Criteria

  • Unlikely to be able to comply with study procedures, as judged by the investigator.
  • Untreated, uncontrolled caries and/or periodontal disease
  • Known or suspected current malignancy
  • History of chemotherapy within 5 years prior to surgery
  • History of radiation in the head and neck region
  • History of other metabolic bone diseases, e.g. Paget's disease, hyperparathyroidism, fibrous dysplasia or osteomalacia
  • A medical history that makes implant insertion unfavourable
  • Need for systemic corticosteroids
  • Current or previous use of intravenous bisphosphonates (esp. zoledronic acid)
  • Current or previous use of oral bisphosphonates
  • History of bone grafting and/or sinus lift in the planned implant area
  • Current need for bone grafting and/or sinus lift in the planned implant area
  • Present alcohol and/or drug abuse
  • Involvement in the planning and conduct of the study (applies to both Astra Tech AB staff or staff at the study site)
  • Previous enrolment in the present study.
  • Participation in a clinical study during the last 6 months.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00745121). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search